NATURE REVIEWS DRUG DISCOVERY

Scope & Guideline

Illuminating the path to novel drug therapies.

Introduction

Welcome to your portal for understanding NATURE REVIEWS DRUG DISCOVERY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1474-1776
PublisherNATURE PORTFOLIO
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationNAT REV DRUG DISCOV / Nat. Rev. Drug Discov.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

Nature Reviews Drug Discovery is dedicated to providing comprehensive reviews and insights into the evolving landscape of drug discovery and development. The journal's primary focus lies in facilitating a deeper understanding of the scientific and technological advancements that shape the pharmaceutical industry.
  1. Drug Discovery Mechanisms:
    The journal extensively covers the mechanisms underlying drug discovery, including target identification, lead optimization, and preclinical development, highlighting innovative methodologies and technologies.
  2. Therapeutic Areas:
    Nature Reviews Drug Discovery addresses a wide range of therapeutic areas, including oncology, neurology, infectious diseases, and autoimmune disorders, providing insights into current trends and future directions in these fields.
  3. Emerging Technologies:
    The journal emphasizes the role of emerging technologies in drug discovery, such as artificial intelligence, gene editing, and novel drug delivery systems, showcasing how these innovations can enhance drug development processes.
  4. Clinical Development and Regulatory Landscapes:
    The journal discusses the challenges and strategies associated with clinical trials and regulatory approvals, offering critical analyses of recent FDA approvals and the implications for drug development.
  5. Personalized Medicine and Precision Therapeutics:
    Nature Reviews Drug Discovery explores the advancements in personalized medicine, focusing on how genetic and molecular profiling can inform drug development and improve patient outcomes.
Recent publications in Nature Reviews Drug Discovery reveal several emerging themes and trends that reflect the current priorities and interests of the drug discovery community.
  1. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is rapidly increasing, with a focus on improving target identification, predictive modeling, and optimizing drug design.
  2. Gene Therapy and Genetic Medicines:
    There is a growing emphasis on gene therapy approaches, including CRISPR and RNA-based therapies, which are seen as revolutionary methods for treating genetic disorders and complex diseases.
  3. Immunotherapy Innovations:
    The field of immunotherapy is witnessing significant advancements, particularly in CAR-T cell therapies and bispecific antibodies, which are becoming key areas of research in oncology.
  4. Microbiome Research in Drug Development:
    The role of the microbiome in drug metabolism and therapeutic efficacy is gaining attention, leading to new strategies for drug development that consider microbiome interactions.
  5. Regenerative Medicine and Tissue Engineering:
    Emerging research on regenerative medicine and tissue engineering is highlighting novel therapeutic strategies for treating degenerative diseases and injuries, marking a shift towards more holistic treatment approaches.

Declining or Waning

As the field of drug discovery evolves, certain themes and areas of focus may decline in prominence. Recent analyses indicate a waning interest in specific topics that were previously prominent in the literature.
  1. Traditional Small Molecule Drug Discovery:
    While still relevant, there has been a noticeable shift towards biologics, gene therapies, and advanced therapeutic modalities, leading to a decline in the emphasis on traditional small molecule approaches.
  2. Conventional Monoclonal Antibodies:
    The exploration of conventional monoclonal antibodies is decreasing, as the field moves towards bispecific antibodies, antibody-drug conjugates, and other innovative formats that offer improved efficacy and specificity.
  3. Single-Target Approaches:
    The focus on single-target drug discovery is declining in favor of multi-target strategies that consider the complexity of diseases, particularly in oncology and chronic conditions.
  4. Standard Clinical Trial Designs:
    There is a diminishing focus on traditional clinical trial designs, with increasing interest in adaptive trial designs and real-world evidence to better evaluate drug efficacy and safety.
  5. Cytokine-Based Therapies:
    Interest in cytokine-based therapies appears to be waning, as researchers explore more targeted and less toxic immunotherapeutic options.

Similar Journals

MEDICINAL RESEARCH REVIEWS

Unveiling Insights for Tomorrow’s Health Solutions
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Journal of Pharmacy & Pharmacognosy Research

Empowering Research in Pharmaceutical Sciences
Publisher: JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRESISSN: 0719-4250Frequency: 6 issues/year

Journal of Pharmacy & Pharmacognosy Research, published by JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRES, is a prominent open-access journal established in 2013, headquartered in Antofagasta, Chile. With a focus on the fields of Complementary and Alternative Medicine, Drug Discovery, Pharmaceutical Science, Pharmacology, and Pharmacy, this journal is recognized for its commitment to advancing research and disseminating knowledge within these important areas. With a current impact factor that reflects its academic rigor and relevance, the journal has achieved substantial recognition, evident by its Q2 and Q3 quartile rankings in multiple categories, indicating its growing influence on the scientific community. The Scopus rankings further highlight its standing in pharmacy and pharmacological disciplines, providing a valuable platform for researchers, professionals, and students to share their findings and insights. With its open access model, the journal ensures that high-quality research is available to a global audience, paving the way for collaborative advancements in pharmaceutical sciences.

Journal of Reports in Pharmaceutical Sciences

Advancing Pharmaceutical Knowledge, One Report at a Time.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Bridging research and real-world applications in pharmacology.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0031-6903Frequency: 12 issues/year

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

CURRENT PHARMACEUTICAL DESIGN

Advancing Pharmaceutical Science for a Healthier Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Indian Journal of Pharmaceutical Education and Research

Bridging local insights with global pharmaceutical advancements.
Publisher: ASSOC PHARMACEUTICAL TEACHERS INDIAISSN: 0019-5464Frequency: 4 issues/year

Indian Journal of Pharmaceutical Education and Research, published by the Association of Pharmaceutical Teachers of India, is a pivotal platform for scholarly discussion in the field of pharmacology, toxicology, and pharmaceutics. ISSN 0019-5464, this esteemed journal aims to foster the exchange of innovative research, clinical advancements, and educational practices within the pharmaceutical sciences community. As a Q3-ranked journal in its category as of 2023, it reflects a commitment to upholding the standards of academic excellence and contributes significantly to the ongoing development of pharmaceutical education. The journal is a valuable resource for researchers, professionals, and students, with content spanning various key areas including drug formulation, safety, and the latest trends in pharmaceutical education. By providing open access to its research and reviews, the journal ensures that vital information is disseminated widely, promoting collaboration and learning among stakeholders in the pharmaceutical sector. Based in Bangalore, India, the journal has been instrumental in highlighting regional research while fostering a global dialogue in pharmaceutical sciences. As it continues its journey from 2008 to 2024, it remains dedicated to impacting the field through rigorous peer-reviewed content and engaging with contemporary challenges in healthcare and education.

Future Science OA

Pioneering discoveries for a healthier tomorrow.
Publisher: FUTURE SCI LTDISSN: 2056-5623Frequency: 10 issues/year

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Discovery Medicine

Fostering a vibrant dialogue in the world of medical sciences.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Future Journal of Pharmaceutical Sciences

Exploring the Future of Drug Science and Healthcare Solutions
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.